Adaptive Biotechnologies Corporation (ADPT) - Stock Analysis
Last updated: Mar 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Adaptive Biotechnologies (ADPT) exhibits strong short-term momentum with a recent earnings beat, 52% YoY MRD revenue growth, raised guidance, and technical breakout above the upper Bollinger Band, complemented by favorable biotech sector tailwinds.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross-margin ⢠Operating losses ⢠Elevated leverage ADPT has very high gross margins and strong liquidity but persistent operating losses, negative free cash flow and elevated leverage amid a valuation premium.
Price Behavior
Key Price Behavior Insights: ⢠Below short-term SMA ⢠Accelerating selling ⢠Modest rebound potential Support Level: $14.86 Resistance Level: $16.4â$16.5 Over the last month the stock fell about 9.8% to $14.86, trading below its ~$15.88 last-month SMA and showing accelerating selling (single-session drop ~â6.7%), with immediate support at $14.86 and resistance near $16.4â$16.5.
Sentiment & News
Key News Insights: ⢠Large stake rise ⢠Concentrated buying ⢠SEC filing disclosure Allianz Asset Management disclosed a 305.8% increase in its Adaptive Biotechnologies (ADPT) stakeâadding 242,474 shares to reach 321,774âindicating concentrated institutional buying.
AI Summary
ADPT has shifted from a binary R&D biotech into a bifurcated investment where highâmargin, scaling clonoSEQ MRD testing now drives positive adjusted EBITDA and potential selfâfunding, but the stock's premium valuation and ~$210M debt mean upside depends critically on sustained MRD ASP/pricing, payer adoption and timely pharma backlog conversions or else dilution/refinancing risk will materialize.
Description
Adaptive Biotechnologies is a commercial-stage company that develops immune-based diagnostics and therapeutics, offering sequencing and clinical assays to detect and monitor cancer, infectious diseases and immune-related conditions. Its portfolio includes research and clinical immunosequencing products and laboratory diagnostics for minimal residual disease and past infection detection, and it supports life-science research, clinical diagnostics and drug discovery. The company maintains strategic collaborations with Genentech on neoantigen-directed T-cell therapies and with Microsoft on computational diagnostic efforts; it was incorporated in 2009 and is headquartered in Seattle, Washington.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 25 | Dec 2 | ADPT | Adaptive Biotechnologies Corporation | Adaptive Biotechnologies (ADPT) exhibits strong short-term momentum with a recent earnings beat, 52% YoY MRD revenue growth, raised guidance, and technical breakout above the upper Bollinger Band, complemented by favorable biotech sector tailwinds. | Closed | -8.0% |